Insilico and SK Partner on Neuroimmune Drug Discovery Worth Up to $2.5 Billion
Insilico has entered into a significant collaboration with SK focused on AI-driven drug discovery for neuroimmune conditions. The partnership, valued at up to $2.5 billion, will leverage Insilico's AI platforms to identify and develop novel therapeutic candidates.
The collaboration combines Insilico's generative AI and deep learning capabilities for target identification and molecule design with SK's resources and expertise in pharmaceutical development. Neuroimmune disorders involve interactions between the nervous and immune systems and include conditions such as multiple sclerosis and certain autoimmune neuropathies.
This deal represents one of the larger AI pharmaceutical partnerships seen in recent years, reflecting continued industry confidence in AI-accelerated drug discovery approaches. Insilico has built a reputation for using AI to shorten drug development timelines and reduce costs in the traditional R&D process.